Spontaneous Antigenemia in Loiasis

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT04258670
• Date of registration: 03/02/2020
• Prospective Registration: Yes
• Primary sponsor: Washington University School of Medicine
• Public title: Spontaneous Antigenemia in Loiasis
• Scientific title: Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis
• Date of first enrolment: January 23, 2020
• Target sample size: 60
• Recruitment status: Active, not recruiting
• URL: https://clinicaltrials.gov/show/NCT04258670
• Study type: Observational [Patient Registry]

Countries of recruitment

Cameroon

Contacts

• Name: Philip Budge, MD, PhD
• Affiliation: Washington University School of Medicine

Key inclusion & exclusion criteria

Inclusion Criteria:

- Ability to give informed consent

- Loiasis Mf count > 20,000 Mf/mL

- Resident of study area

- No evidence of severe or systemic comorbidities

- Consent to storage of blood samples for future study

Exclusion Criteria:

- Subject plans to move from the study area during subsequent 12 months



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Loiasis

Lymphatic Filariasis

Intervention(s)

Other: No intervention

Primary Outcome(s)

prevalence of specific cross-reactive L. loa antigens at baseline [Time Frame: 1 day]

Secondary Outcome(s)

Recurrence of cross-reactive antigenemia [Time Frame: quarterly for 1 year]

Secondary ID(s)

201909003

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Centre for Research on Filariasis and other Tropical Diseases

Doris Duke Charitable Foundation